Virtually all human tumors are deficient in gap junctional communication (GJC) and the restoration of GJC by forced expression of connexins reduces indices of neoplasia. The expression of connexin 43 (Cx43) is upregulated by cancer-preventive retinoids and carotenoids which correlates with the suppression of carcinogen-induced transformation in 10T1/2 cells. However, the molecular mechanism for upregulated expression is poorly understood. The retinoic acid receptor antagonist, Ro 41-5253, suppressed retinoid-induced Cx43 protein expression in 10T1/2 cells and the induction of a Cx43 luciferase reporter construct in F9 cells, but did not suppress protein expression or reporter activity induced by the non-pro-vitamin A carotenoid astaxanthin. In contrast, Cx43 induction by astaxanthin, but not by a RARspecific retinoid, was inhibited by GW9662, a PPAR-g antagonist. Neither compound required protein synthesis for the induction of Cx43 mRNA, nor was the 5.0 h half-life of Cx43 mRNA altered, indicating direct transcriptional activation. The responsive region was found within À158 bp and +209 bp of the transcription start site. Site directed mutagenesis of a GC-box in this region increased basal levels of transcription and loss of retinoid responsiveness. Simultaneous treatment with a retinoid and h-carotene or astaxanthin resulted in supraadditive Cx43 expression, again indicating separate mechanisms of gene regulation. D 2005 Published by Elsevier B.V. 0925-4439/$ -see front matter D 2005 Published by Elsevier B.V.
Introduction

Cancer prevention
Prevention is always better than cure, and this old adage is particularly germane in the case of cancer where cure, if at all possible, is frequently associated with highly cytotoxic agents and/or invasive procedures. With our growing understanding of the molecular etiology of cancer as being caused by specific mutations in genes associated with cell cycle control, apoptosis and DNA repair enzymes, it has become apparent that strategies to limit DNA damage and/or increase the probability of DNA repair by inhibiting aberrant proliferation will decrease cancer incidence rates [1] . Likewise, our growing understanding of the epidemiology of cancer on a worldwide basis has led to the realization that the dramatic differences in site-specific cancer incidence rates in different geographic locations are primarily a consequence of lifestyle differences rather than genetic differences in the affected populations. In a seminal study commissioned by the U.S. National Cancer Institute, it was estimated that some 70% of human cancer in the U.S. was a consequence of lifestyle and is thus, in theory at least, preventable [2] . Unfortunately, identifying etiological agents does not necessarily convert into effective cancer prevention. As a prime example would be the very limited success in limiting the use of tobacco products, first identified in the 1940s as responsible for the epidemic of lung cancer incidence in the West and currently considered to cause some 20-30% of cancer in Western countries [3] . Other examples would be the rapidly rising incidence of obesity in Western populations which is linked to the increased incidence of many diseases including cancer, particularly of the breast and prostate, and the dramatically increasing rates of melanoma in fair-skinned populations-a phenomena probably linked to ease of travel to warmer climates with high UV irradiation.
Primary cancer preventive strategies are those aimed at removing sources of carcinogen exposure, be they chemical in the case of tobacco, physical, in the case of UV exposure or mutifactorial in the case of diet and obesity. As exemplified above, such strategies have had mixed success. Others have been more successful, such as the widespread elimination of asbestos, controls on aflatoxin contamination of foods and strict limits on exposure to ionizing radiation. However, it is clear that cancer incidence rates at many anatomic sites have remained essentially unchanged over approximately 70 years of observation. Success in primary prevention can be observed in the recently decreasing incidence rates of lung cancer, particularly in men, which parallel earlier declines in tobacco consumption [3] . Also of note are the decreasing rates of stomach cancer in both sexes; this is considered to be an inadvertent consequence of the widespread introduction of refrigeration and canning to preserve meats leading to the decreased consumption of salt-cured meat products containing carcinogenic nitrosamines.
Secondary cancer prevention relates to inhibiting the consequences of carcinogen exposure. This strategy and the use of retinoids or carotenoids to inhibit the process of carcinogenesis will be the subject of this review. Unfortunately, this strategy has had only limited success in clinical situations either as a consequence of inappropriate intervention, dosage or, in the case of retinoids unacceptable toxicity. Recently however inhibitors of cyclooxygenase-2 (COX-2), the inducible form of this enzyme shown to be elevated in preneoplastic and neoplastic tissues, have shown effectiveness in decreasing the incidence of pre-neoplastic polyps in the colon in individuals suffering from an inheritable form of this disease [4] .
Tertiary cancer prevention relies upon the identification and removal of pre-neoplastic lesions and the success of this approach can be readily observed with the dramatically decreasing rates of uterine cancer resulting from the widespread application of cervical cancer screening (the Pap test) beginning in the 1940s. At present this approach is unfortunately limited to tissues that are easily accessed. In 1987 we reviewed the prospects for cancer chemoprevention in some detail with emphasis on the epidemiological, molecular and public health aspects of cancer prevention [5] . There is currently intense interest in the development of molecular tools for the remote detection of aberrant cells.
Retinoids and carotenoids as cancer preventive agents
Because the physiologically active form of vitamin A, retinoic acid, is derived from carotenoid precursors either directly in the diet, or indirectly through consumption of animal products, there is a natural tendency to group both classes of compounds into a single entity in terms of cancer prevention. However, as will be discussed below, it is now apparent that certain carotenoids which are chemically incapable of being converted to retinoic acid (i.e. the non-pro-vitamin A carotenoids) possess chemopreventive activity in experimental models of cancer and have been associated with lower cancer risk in epidemiological studies. Structures of key molecules are shown in Fig. 1 . Complicating this separation on the basis of chemistry is the knowledge that both agents upregulate the expression of the putative tumor suppressor gene, connexin 43 (Cx43), however this upregulation appears to involve separate molecular pathways, again emphasizing the need for a separate discussion of retinoids and carotenoids as cancer preventive agents. Because the upregulation of Cx43 appears central to the ability of both classes of agent to inhibit neoplastic transformation in cell cultures, the role of connexin-mediated cell-cell communication will be discussed first so that the actions of retinoids and carotenoids can be viewed in this context.
Proposed role of cell-cell communication in suppressing carcinogenesis
Much of the evidence linking retinoids and carotenoids with enhanced gap junctional communication (GJC) stems from work using the C3H/10T1/2 (10T1/2) cell model of in vitro cell transformation [6] . In this model cells are seeded at a low initial density, treated for 24 h with a chemical carcinogen, then allowed to proliferate to form a confluent, growth inhibited monolayer. In the absence of carcinogen exposure, cells form a monolayer with low rates of proliferation which is stable over many weeks of culture. Carcinogen exposure results in a small proportion of surviving cells, typically b1%, becoming carcinogen-initiated. These cells are latent until approximately 4 weeks after carcinogen exposure at which time a few individual cells within a colony of initiated cells begin proliferation to form a focus of morphologically aberrant cells which progressively invade surrounding normal cells to form a transformed focus (Fig 2) . This model has been widely accepted as a quantitative assay for chemical and physical carcinogens [7] . We have shown that when retinoids or carotenoids are added after carcinogen exposure they are capable of suppressing the formation of transformed foci [8] [9] [10] .
The actions of both classes of compound in inhibiting transformation in 10T1/2 cultures can be summarized as follows:
1. Inhibition occurs in the post-initiation phase of carcinogenesis and does not thus interfere with carcinogeninduced DNA damage or its processing. 2. Inhibition is reversible and thus does not involve selective cytotoxicity to initiated cells or the irreversible differentiation of such cells. 3. Inhibition does not involve activating the immune system as no such effector cells exist in this cloned fibroblast population. 4. Inhibition is not due to blocked expression of the transformed phenotype since treatment after the transformation event does not inhibit focus formation. 5. Inhibition of transformation is tightly correlated with the ability of these agents to enhance cell/cell interactions, later discovered to be due to upregulated gap junctional communication [11, 12] . 6. For the carotenoids, both non-pro-and pro-vitamin A molecules were active; a finding that appeared to rule out conversion to retinoid-like molecules [13] .
Connexins and carcinogenesis
It is now well-established that, with the obvious exception of red blood cells, virtually all cells types are in junctional communication with their neighbors, or in the case of leukocytes, can form junctions after activation [14] . In addition, it is equally well-established that most, if not all, human solid tumors are deficient in GJC [15] and, as we have shown in the human cervix and oral cavity, downregulated expression of Cx43 is an early event in carcinogenesis being detected in dysplasia and leukoplakia respectively [16] . Downregulated expression seems only rarely due to inactivating mutations-although giving rise to several other diseases [17] -instead epigenetic silencing via DNA methylation or disrupted trafficking of connexins to the plasma membrane of tumor cells appear frequently responsible for disrupted GJC [18, 19] . The loss of GJC in tumors, and as discussed below, the restoration of some aspects of a normal phenotype after the correction of this defect by molecular or pharmacological means has led to the concept that connexins function as tumor suppressor genes [20, 21] . A model for growth control via junctional communication is shown in Fig. 3 .
Gap junction structure
Gap junctions are composed of small water-filled pores that directly connect the cytoplasm of adjacent cells and allow the transfer of water-soluble molecules b1000 Da. Each junction, termed a connexon, is formed by the assembly of 6 connexin proteins donated by one cell with six connexin proteins donated by the adjacent cell. These trans-membrane proteins each possess 6 highly conserved cysteine residues in their extracellular domains; these are believed to form sulfhydryl bridges with cysteine residues donated by the adjacent cell to stabilize these interactions and form a tight seal, preventing the entry of extracellular ions such as calcium into the cytoplasm [22] . This organization is depicted diagrammatically in Fig. 4 .
Modulation of connexin function by molecular means
To specifically address the functional consequences of disrupted GJC, several investigators have manipulated tumor cells to re-establish junctional communication by the use of molecular constructs to force the expression of connexins. Comparable studies utilizing normal cells have been compromised by technical problems of transfection and selection, and by the fact that most normal cells in culture are junctionally competent. A consistent finding after forced expression of Cx43 in malignant cells has been a decrease in their malignant potential. Using a tetracyclineinducible promoter system to drive Cx43, we have shown in a human cervical carcinoma cell line and in a human fibrosarcoma cell line, that in comparison to non-induced cells, Cx43 expression resulted in dramatically decreased anchorage independent growth and a decreased ability to form tumors in immunocompromised nude mice [16, 23] . Using constitutive promoters others have found similar effects in a variety of human and animal malignant cell lines. The studies have been recently reviewed [24] . However, we have cautioned that when using constitutive promoters to express connexins, the interpretation of results may be problematic because of extensive clonal heterogeneity in cultured cells [19] .
As an alternative approach to probe connexin function, a number of mouse strains have been created in which different connexin family members have been knocked out by homologous recombination or by targeted expression of dominant negative connexin mutants (reviewed in [25] ). Notable here is the observation that mice in which connexin 32, a connexin extensively expressed in the liver, is inactivated becomes more susceptible to liver carcinogenesis [26] , and hemizygous deletion of Cx43 results in mice susceptible to lung carcinogenesis [27] .
The ability of neoplastic cells to grow in suspension-a phenomenon called anchorage-independent growth-has long been used to distinguish neoplastic cells from their normal counterparts. In normal epithelial and fibroblastic cells contact with extra-cellular matrix leads to the formation of focal contacts which allow for cell replication after mitogenic stimulus. In the absence of such contacts, normal cells will not proliferate and frequently undergo apoptosis. The lack of this requirement in tumor cells as a result of inappropriate expression of this kinase presumably reflects their acquired ability to migrate through and proliferate in inappropriate locations. The ability of forced expression of Cx43 to restore this requirement for cell proliferation [16, 23] , was unexpected but fits into some recently generated clinical data. Here, the administration of fairly high doses of supplemental lycopene to patients with prostate cancer for 3 weeks prior to radical prostatectomy was found to be associated with the increased expression of Cx43 and decreased pathological severity of treated versus control tumors; a finding most easily explained by induction of apoptosis in these tumors [28] . This has been confirmed by a separate group [29] , while in a study conducted in India, even a small dietary supplementation (2 mg/day) to patients after prostatectomy was reported to result in improved clinical parameters and survival [30] . These data all indicate that, at least in the case of lycopene and prostate cancer, carotenoids could have therapeutic potential. Certainly, recent data in mice strongly supports such a role. The oral administration of a mixture of lycopene, selenium and a-tocopherol virtually completely blocked the development of abnormal pathology in a transgenic model in which 100% of control animals developed prostate cancer [31] .
The influence of lycopene on the proliferation of carcinoma cells appears not limited to its ability to modulate Cx43 expression. In studies conducted by others, growth stimulation of MCF7 mammary cancer cells by IGF-I was markedly reduced by physiological concentrations of lycopene [32] . Lycopene treatment markedly reduced the IGF-I stimulation of tyrosine phosphorylation of insulin receptor substrate 1 and binding capacity of the AP-1 transcription complex, suggesting that effects on proliferation were due to interference in IGF-I receptor signaling [32] . Additionally, reductions in androgen signaling have been reported [33] . Interactions appear not limited to cell culture studies as epidemiologic investigations have shown a strong inverse correlation between plasma lycopene and circulating IGF-1 [34] . IGF-1 is an important mitogen for prostate cells, thus reports of lycopene/IGF-1 interactions both in terms of production of and responses to IGF-1 could be highly significant to the role of lycopene as a chemopreventive and possibly therapeutic agent in prostate cancer.
Mechanisms by which retinoids and carotenoids upregulate Cx43 expression
Both retinoids and carotenoids upregulate expression at the mRNA and protein level, these increased Cx43 mRNA levels are not inhibited by cyclohexamide and activity does not involve an increase in mRNA half-life, indicating direct transcriptional activation [49] . However differences between retinoids and carotenoids do exist. Pharmacological inhibitors of retinoid nuclear receptors (RARs) inhibited the activity of retinoids at the transcriptional and protein level, while not inhibiting the activity of nonpro-vitamin A carotenoids such as astaxanthin. In contrast, a specific inhibitor of tyrosine-based PPAR-g ligands, 2-Chloro-5-nitrobenzanilide (GW9662) [35] , blocked the ability of astaxanthin, but not a retinoid, to upregulate Cx43 expression [53] . The interaction of carotenoids with the PPAR family of nuclear receptors appears far more likely than with the RAR family; PPARs can be activated by a wide variety of lipophilic molecules including fatty acids, rosiglitazone derivatives and synthetic tyrosinebased compounds. The ligand binding cavity of PPAR-g is a large T-shaped, mainly hydrophobic, pocket which allows for binding and activation by large number of diverse ligands [36] . Additional studies of interactions of carotenoids with PPAR-g are on-going. The reason that carotenoids seem unlikely to be able to interact directly with RARs or RXRs is that interactions between retinoic acid and the nuclear receptors is now known to involve the insertion of the carboxylic acid moiety at the end of the polyene chain into a pocket in the receptor which subsequently shifts conformation and encloses the ligand [37, 38] . Both the carboxylic acid group and the length of the polyene chain appear critical for RAR activation [39] . Thus, although h-carotene and other pro-vitamin A carotenoids possess obvious structural similarities to retinoic acid ( Fig. 1) it is difficult to envision how hcarotene itself can bind to and activate RAR. None of the other carotenoids tested would seem better suited for RAR activation.
Our data do provide evidence for the bioconversion of hcarotene to a retinoid, in that the RAR antagonist Ro41-5253 partially inhibited Cx43 upregulation by this provitamin A carotenoid but not by non-pro-vitamin A carotenoids. This agrees with previous work indicating that some conversion of h-carotene to retinoic acid occurs in 10T1/2 cells [40] .
From a pharmacological perspective, the activity of lycopene as a regulator of gene expression seems unlikely due to the parent molecule-a straight-chain polyunsaturated hydrocarbon-but seems more likely a consequence the production of biologically active oxidation products. These molecules could be formed as a consequence of cellular metabolism, or the active agent(s) could be produced directly as a consequence of oxidative modification of the parent carotenoid molecule. If cellular metabolism is involved then the responsible enzymes must be widely expressed, since as discussed above, lycopene has been shown active in this respect in mouse and human fibroblasts, and in human oral carcinoma cells. There is evidence that the recently discovered beta, beta-carotene 9V,10V-dioxygenase can cleave lycopene at the 9,10 position [41] . The products of such cleavage, presumably C-9 and C-31 aldehydes and alcohols, would still not possess the betaionone ring required of retinoids for activity, but could still activate other nuclear receptors and lead to transcriptional modulation. Three oxidation products of lycopene have been described, but none seem to possess the desired potency to fully explain the activity of lycopene on Cx43 expression. A cyclic compound with a five membered ring, 2,6-cyclolycopene-1, 5-diol, was described by Khachik to be present in human serum after consumption of tomato products [42] . Its formation is probably a result of initial oxidation to an epoxide followed by hydrolysis. When tested in 10T1/2 cells it was marginally more potent than lycopene itself in regulating Cx43 expression [43] . However it seems unlikely that this derivative is responsible for lycopene's activity since nearly quantitative conversion to this product would be required, yet the concentration in human serum is only about 10% of that of lycopene [42] . Moreover, it is not known if this molecule is produced in cell culture after lycopene treatment. Similar conclusions can be made regarding the biological significance of the second lycopene derivative, 2,7,11-trimethyl-tetradecahexaene-1,14-dial, produced as a consequence of chemical oxidation of lycopene with hydrogen peroxide/osmium tetroxide. While this compound also upregulates Cx43 expression in 10T1/2 cells, it appears to be less potent than lycopene itself, which suggests that its contribution is minimal [44] . Again, it is not known if this dial is produced in vivo or in cell culture. A third molecule, acyclo-retinoic acid, also potentially formed by oxidation of lycopene has been evaluated in 10T1/2 cells. Although possessing activity, this was 500-fold lower than that of lycopene itself as an inducer of Cx43 expression, again implying a minimal contribution to the activity of lycopene in this respect [45] . These studies of lycopene metabolites, although essentiality negative in not having discovered a derivative more active than lycopene itself, nevertheless to illustrate the structurally diverse nature of carotenoid derivatives capable of being spontaneously produced and which may have generegulatory activity. While these oxidation products can all be expected to be lipid-phase antioxidants, by virtue of their retention of some polyunsaturated conjugated double bonds, as pointed out earlier, antioxidant activity per se does not seem to explain activity. Potent antioxidants such as alphatocopherol do not upregulate Cx43 expression and the in vitro antioxidant activity of diverse carotenoids did not correlate with their ability to modulate Cx43 expression [46] . It remains to be determined if any of these products can activate PPAR gamma, known to be a highly promiscuous nuclear receptor, explaining how all these diverse compounds produce a common response. Studies of oxidation products of the cyclic carotenoids, including hcarotene and canthaxanthin, have been performed, however the results have been inconsistent: While we were unable to demonstrate a conversion of canthaxanthin to the active retinoid, 4-oxo-retinoic acid [40] , others have presented evidence, utilizing the same 10T1/2 cell line, that that conversion of canthaxanthin to 4-oxo retinoic acid was responsible for some or all of its ability to modulate Cx43 expression [47] .
Analysis of the Cx43 promoter sequence
The two Cx43 reporter constructs were employed to examine the requirements for carotenoid/retinoid expression. Both have been previously characterized: pCx2400luc, which contains the region of the human Cx43 promoter between À2200 bp and +209 bp of the transcriptional start site, and pCx350luc, a smaller fragment of the human Cx43 promoter containing a region between À158 bp and +209 bp of the transcription start site [48] . Because of poor transfection efficiencies in 10T1/2 cells, we used F9 mouse embryonic cancer cells previously shown to be responsive to retinoids and carotenoids [46] . Both the pan-RAR agonist tetrahydrotetramethylnaphalenylpropenyl benzoic acid (TTNPB) and carotenoid treatment resulted in the upregulated activity of both of the Cx43 promoter constructs [49] . Although the smaller pCx350luc construct was considerably less active, nevertheless, in terms of fold-induction, the ratio of induction by TTNPB and carotenoids was similar for both constructs and approximated the increased Cx43 expression detected at the protein level in 10T1/2 cells [46, 50] . These data demonstrate that in F9 cells both TTNPB and carotenoid treatment upregulate Cx43 expression at the transcriptional level.
Identification of promoter elements responsive to TTNPB or carotenoid treatment
Since the Cx43 promoter does not contain a canonical RAR-response element (RARE) or PPAR-response element, we used computer analysis of the human, mouse and rat sequences of the Cx43 promoter (À2200 bp and +209 bp) to identify evolutionally conserved potential promoter elements that have previously been demonstrated to be responsive to retinoids in other contexts (Fig. 5 ). After eliminating those sites that required protein synthesis, shown in previous experiments not to be required, we identified three candidate sites: a Sp1 GC-box, a TCF/LEF motif and a nuclear receptor half-site. Only the Sp1 site appears to be involved in the transcriptional control of this promoter. In order to confirm the involvement of this motif, we created a construct, pCx350-SP1M-luc, in which the GC-box motif was mutated. The elimination of this site enhanced basal promoter activity by 6-fold, when compared to the original wild-type construct pCx350luc. The increased basal level of expression may result from the loss of binding of a repressor protein such as Sp3, although as stated above, we were unable to detect this by electrophoretic mobility-shift assays. Whereas expression from the wild-type construct was significantly increased by retinoid and carotenoid treatment, the mutant failed to significantly respond to any of the treatments. There was however a slight trend seen: Treatment with TTNPB or hcarotene resulted in a N25% lower activity relative to the untreated mutant control, whereas treatment with astaxanthin or lycopene resulted in a 20% upregulation, however these changes were not significant ( PN0.05) [49] . These data indicate that while both retinoids and carotenoids influence Cx43 promoter activity by interacting with genetic elements within the region À158 bp to +209 bp of the transcription start Table 1 Combined treatment with a retinoid and various carotenoids results in increased expression from a luciferase Cx43 reporter construct and of Cx43 protein than can be achieved by each agent alone For the reporter assays, F9 cells were treated for 48 h with the indicated compounds alone, at concentrations shown to induce maximum gene expression, or with retinoid/carotenoid combinations. For protein expression assays, 10T1/2 cells were treated for 72 h prior to assay; note that carotenoid concentrations were reduced 10-fold because higher concentrations in combination appeared toxic. Results show the means of 2 separate experiments. N/A, not applicable; ND, not done. site, the actions of retinoids and non-pro-vitamin A carotenoids differ markedly. First, the retinoid TTNPB and, to a lesser extent, the pro-vitamin A carotenoid h-carotene require interactions with RARs for activity. This is not the case for the non-pro-vitamin A carotenoids astaxanthin or lycopene which appear to interact with PPAR-g. The nature of the interactions of these two nuclear receptors is currently being studied.
The separate interactions of retinoids and carotenoids with the Cx43 promoter suggest that simultaneous treatment with retinoids and non-pro-vitamin A carotenoids could result in superinduction of Cx43. To test this possibility F9 cells were transfected with the Cx43luciferease reporter construct and treated with combinations of TTNPB and carotenoids at concentrations shown to each induce maximum induction. We observed an increase in promoter activity greater than that observed with TTNPB or carotenoid alone [49] . This was especially evident in astaxanthin/TTNPB treated cells, indicating that two types of molecule interact independently with this promoter. This experiment was repeated with 10T1/2 cells; here Cx43 protein expression was measured by Western blotting. Combined treatments with TTNPB and astaxanthin or hcarotene resulted in levels of Cx43 expression far greater than that achieved by either compound alone (Table 1; Vine et al., submitted for publication).
In conclusion, the results presented here support the hypothesis that the two different classes of chemopreventive agents-retinoids/provitamin A carotenoids and the nonprovitamin carotenoids-operate through separate mechanisms. If these separate mechanisms can be activated in a clinical context, combined treatment with a retinoid and a potent non-provitamin A carotenoid such as astaxanthin may result in effective chemoprevention without the toxicity associated with retinoids.
